Initiating Coverage of CR Pharma With Narrow Moat Rating and HKD 13.20 FVE
We initiate coverage on China Resources Pharmaceutical (3320 HK) with a narrow moat rating and a fair value estimate of HKD 13.20 per share. This...
449 Views
"Donkey Skin" Rhymes With "Shark Fin" Update
Recall that E-Jiao, a Traditional Chinese Medicine made from donkey skin, is one of China Resources Pharmaceutical Group (3320 HK) 's leading...
329 Views
China Drug Distribution: More "Two Invoice" Changes
The restructuring of China's drug distribution industry continues with Baiyunshan Phrmcl Hldgs Co Ltd (874 HK)'s pending buyout of Walgreens Boots...
428 Views
Walgreens Invests in Sinopharm Retail Arm
Walgreens Boots Alliance Inc (WBA US) has agreed to buy a 40% stake in Sinopharm Group Co H (1099 HK) 's Guoda Drug Store chain (held by...
507 Views
Shanghai Pharma Gets Cardinal Health Deal
Shanghai Pharmaceuticals H (2607 HK) has agreed to acquire Cardinal Health Inc (CAH US) 's China distribution business for US$1.2 billion (subject...
492 Views